VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

<p>Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 […]</p>
<p>The post <a href="https://forextv.com/top-news/vyne-therapeutics-reports-third-quarter-2023-financial-results-and-provides-business-update/">VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>